VPHI.F Stock Overview
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Valeo Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.11 |
| 52 Week High | CA$0.52 |
| 52 Week Low | CA$0.10 |
| Beta | 2.53 |
| 1 Month Change | -15.37% |
| 3 Month Change | -39.19% |
| 1 Year Change | -67.29% |
| 3 Year Change | -86.92% |
| 5 Year Change | n/a |
| Change since IPO | -86.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| VPHI.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.2% | -2.2% | -3.7% |
| 1Y | -67.3% | 11.6% | 20.5% |
Return vs Industry: VPHI.F underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: VPHI.F underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| VPHI.F volatility | |
|---|---|
| VPHI.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VPHI.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine VPHI.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 100 | Steve Saviuk | www.valeopharma.com |
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson’s disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic.
Valeo Pharma Inc. Fundamentals Summary
| VPHI.F fundamental statistics | |
|---|---|
| Market cap | US$11.11m |
| Earnings (TTM) | -US$20.65m |
| Revenue (TTM) | US$39.43m |
0.3x
P/S Ratio-0.5x
P/E RatioIs VPHI.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VPHI.F income statement (TTM) | |
|---|---|
| Revenue | CA$54.29m |
| Cost of Revenue | CA$40.84m |
| Gross Profit | CA$13.44m |
| Other Expenses | CA$41.88m |
| Earnings | -CA$28.43m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 24.76% |
| Net Profit Margin | -52.37% |
| Debt/Equity Ratio | -138.2% |
How did VPHI.F perform over the long term?
See historical performance and comparison